OBJECTIVE:To observe the clinical efficacy and safety of Shengui capsule in treating severe congestive heart failure(CHF).METHODS: 68 patients with severe CHF were randomly divided into 2 groups:34 patients(control group) were treated with routine therapy(rest,oxygen inhalation,inotropic agents and diuretic agents,vasodilators and symptomatic treatment) for 4 weeks,and another 34 patients with routine therapy plus 0.9 g Shengui capsule tid for 4 weeks(trial group).HR,BP,ECG,CD(Color Doppler),ANF(atrial natriuretic peptide),electrolytes and SCr before and after treatment were compared between the two groups.RESULTS: The cardiac function was improved and ANF level was down-regulated in patients treated with Shengui capsule,showing significant difference as compared with control group(P

0 05) CONCLUSION:UH is effective and safe in treatment of congestive heart failure and its ARDs are rare It is worth popularizing in clinical use

Objective:To investigate the curative effect of Xinbao on patients with sick sinus syndrome(SSS). Methods: 38 patients with SSS were randomly divided into 2 groups: one (A group) taking oral Xinbao and the other (B group) taking xinxianan as control on the base of routine treament. 12 lead surface electrocardiogram and Holter were recorded in all patients before and after treatment. Results: Mean heart rates of the groups were obviously increased after treatment( P 0.05). Conclusion: Xinbao may be a effective and safe drug for treating SSS.